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Abstract 
Background: 
 Glaucoma, an optic neuropathy, is a worldwide leading cause of visual impairment 
and blindness. It is a neurodegenerative disease associated with loss of Retinal Ganglion 
Cells and a raised intraocular pressure (IOP) which is the modifiable risk factor for 
glaucoma. It is an important cause of blindness in the developing world and a major 
health burden in the developed world. Primary open angle glaucoma (POAG) is 
characterized by chronically elevated IOP with optic neuropathy and the cause is 
unknown for the elevated IOP. Reduction of IOP with less complications or adverse 
effects remains the mainstay therapy for the first-line treatment of glaucoma. Two or 
more medications are needed to reach a target IOP to arrest further visual loss in many 
patients with POAG. The drugs commonly used to reduce IOP in glaucoma include 
topical prostaglandin analogues like bimatoprost, beta-blockers like timolol, alpha-
agonists like brimonidine, carbonic anhydrase inhibitors like dorzolamide, and 
parasympathomimetics. Fixed drug combinations have been approved for treatment of 
glaucoma. The available fixed combination drugs in the market are timolol 0.5% 
combined with bimatoprost, dorzolamide or brimonidine. Neuroprotection approach 
prevents neuronal injury or promotes neuronal recovery and protects the RGC from 
glaucomatous injuries. This study is undertaken with the aim to compare and evaluate the 
efficacy and safety of a fixed drug combination of 0.2% brimonidine and 0.5% timolol 
with the effect of 0.5% timolol administered as monotherapy in patients with POAG. 
 
Objective  
 To study the Intra Ocular Pressure lowering effect of fixed dose combination of  
Brimonidine-Timolol with Timolol monotherapy in patients with Primary Open-Angle 
Glaucoma and to assess the effects of fixed dose combination of Brimonidine-Timolol  
on visual acuity and visual field changes. 
 
Methods  
 Single centre, prospective, open label, parallel group, comparative study 
conducted for a period of 12 weeks at Ophthalmology department, Govt. Stanley Medical 
College and Hospital, Chennai-1. The study was commenced after obtaining approval 
from the Institutional Ethics Committee. Patients with Primary Open Angle Glaucoma 
were screened by detailed medical history and ocular examination. A total of 60 patients 
satisfying the selection criteria were included in the study. After getting informed consent 
they were randomized  into 2 groups.  Group A and Group B. Each group consisting of 
30 patients. Group A patients [Test group]: Fixed dose combination of Brimonidine-
Timolol eye drop instilled twice daily. Group B patients:   Timolol 0.5% eye drop 
instilled twice daily. After enrollment into the study and initiation of the study drugs, the 
follow-up was done after 2 weeks, 4 weeks,  8 weeks and 12 weeks.  After 12 weeks of 
study period the patients were followed up in the Ophthalmology department. The 
primary efficacy end point was the change from baseline intraocular pressure to the target 
pressure. Safety was assessed in terms of ocular and systemic adverse effects both 
subjective and objective.   
Results  
  Both timolol monotherapy and brimonidine-timolol fixed drug combination are 
effective agents in reducing intraocular pressure throughout the study period when 
measured at 2
nd
, 4
th
, 8
th
 and 12
th
 weeks. When efficacy of brimonidine-timolol fixed 
combination was compared with timolol monotherapy,  brimonidine-timolol fixed 
combination was more effective in reducing IOP compared to timolol alone. Comparing 
to timolol group, mean IOP was markedly reduced in FDC BT group at the end of 
treatment, p<0.05. There was no significant changes in CCT, visual field changes and 
vital parameters. Comparing to Timolol group, patients in FDC BT group had less side 
effects. There was no serious adverse effects noted in both groups. 
Conclusion 
 In our study both Fixed drug dose combination of Brimonidine-Timolol and 
Timolol monotherapy have been shown to be efficacious in POAG. Compared to Timolol 
monotherapy, FDC Brimonidine-Timolol therapy has shown a more significant reduction 
in IOP. Moreover, FDC Brimonidine-Timolol therapy was found to have produced less 
number of side effects in comparison.  Thus based on the results of our study, it can be 
concluded that brimonidine-timolol fixed combination is more effective and safer in 
lowering IOP in comparison to Timolol monotherapy for the treatment of primary open 
angle glaucoma. In addition, the neuroprotective effects of brimonidine, could prove to 
be beneficial on arresting the progression of the disease on long term.  
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